ArticleBMC medical imaging2025
Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomic analysis of multiple MRI sequences for diagnosing liver cancer vs. focal nodular hyperplasia.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo develop and validate radiomics and deep learning models based on Gd-EOB-DTPA enhanced MRI for differentiation between hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase (HBP).
methods112 patients from three hospitals were collected totally. 84 patients from hospital a and b with 54 HCCs and 30 FNHs randomly divided into a training cohort (n = 59: 38 HCC; 21 FNH) and an internal validation cohort (n = 25: 16 HCC; 9 FNH). A total of 28 patients from hospital c (n = 28: 20 HCC; 8 FNH) acted as an external test cohort. 1781 radiomics features were extracted from tumor volumes of interest (VOIs) in the pre-contrast phase (Pre), arterial phase (AP), portal venous phase (PP) and HBP images. 512 deep learning features were extracted from VOIs in the AP, PP and HBP images. Pearson correlation coefficient (PCC) and analysis of variance (ANOVA) were used to select the useful features. Conventional, delta radiomics and deep learning models were established using machine learning algorithms (support vector machine [SVM] and logistic regression [LR]) and their discriminatory efficacy assessed and compared.
resultsThe combined deep learning models demonstrated the highest diagnostic performance in both the internal validation and external test cohorts, with area under the curve (AUC) values of 0.965 (95% confidence interval [CI]: 0.906, 1.000) and 0.851 (95% CI: 0.620, 1.000) respectively. The conventional and delta radiomics models achieved AUCs of 0.944 (95% CI: 0.779–0.979) and 0.938 (95% CI: 0.836–1.000) respectively, which were not significantly different from the deep learning models or each other (P = 0.559, 0.256, and 0.137).
conclusionThe combined deep learning models based on Gd-EOB-DTPA enhanced MRI may be useful for discriminating HCC from FNH showing iso-or hyperintensity in the HBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.